Daily Sepsis Research Analysis
Analyzed 43 papers and selected 3 impactful papers.
Summary
The strongest papers address prevention, mechanistic stratification, and antimicrobial resistance in sepsis-related disease. A randomized phase 1/2 trial evaluated a maternal hexavalent group B Streptococcus vaccine, while an integrated single-cell and spatial transcriptomic study identified etiology-specific neutrophil states and the THBS1-CD36 axis in acute lung injury. A systematic review and meta-analysis documented a severe and worsening pediatric antimicrobial-resistance crisis in Pakistan.
Research Themes
- Maternal vaccination for prevention of neonatal group B Streptococcus disease
- Multi-omics dissection of sepsis-associated acute lung injury
- Pediatric antimicrobial resistance and sepsis surveillance
Selected Articles
1. Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial.
This randomized phase 1/2 trial evaluated an investigational maternal hexavalent group B Streptococcus polysaccharide-protein conjugate vaccine in non-pregnant and pregnant participants and their infants. The study directly addresses prevention of neonatal invasive GBS disease, a major cause of infant morbidity and mortality for which no licensed vaccine currently exists.
Impact: A successful maternal GBS vaccine could prevent neonatal bloodstream infection, sepsis, meningitis, and mortality through transplacental antibody protection. The randomized pregnancy-focused development pathway is a major translational step toward a globally relevant preventive intervention.
Clinical Implications: The findings support continued clinical development of maternal GBS vaccination and inform future efficacy trials designed to measure prevention of neonatal invasive disease. Implementation would require assessment of gestational timing, infant antibody persistence, vaccine safety, cost-effectiveness, and regional GBS epidemiology.
Key Findings
- A randomized phase 1/2 trial evaluated the investigational hexavalent GBS6 vaccine in non-pregnant and pregnant females and their infants.
- The study targeted prevention of neonatal GBS disease, a major cause of infant morbidity and mortality.
- The trial represents clinical development of a maternal vaccine despite the absence of any licensed capsular polysaccharide conjugate GBS vaccine.
Methodological Strengths
- Randomized phase 1/2 design including both non-pregnant and pregnant participants.
- Direct evaluation of maternal immunization and its relevance to infant protection.
Limitations
- The supplied abstract does not provide the complete efficacy, immunogenicity, or safety results.
- Phase 1/2 data cannot establish population-level prevention of neonatal invasive GBS disease.
- Long-term infant protection and effectiveness across different geographic serotype distributions require further study.
Future Directions: Large phase 3 efficacy trials should assess prevention of neonatal invasive GBS disease, stillbirth, and infant mortality, while evaluating maternal and infant safety, antibody correlates of protection, durability, and cost-effectiveness in diverse settings.
Group B Streptococcus (GBS) disease is a major cause of infant morbidity and mortality. Capsular polysaccharide conjugate GBS vaccines have been evaluated for decades; however, none is licensed. This phase 1/2 trial evaluated an investigational maternal hexavalent polysaccharide-protein conjugate GBS vaccine (GBS6) in non-pregnant females and pregnant participants and their infants. In stage 1 (conducted in South Africa), healthy non-pregnant participants received GBS6, GBS6 + aluminum phosphate (AlPO
2. Integrated single-cell and spatial transcriptomic atlas of multi-etiology acute lung injury reveals etiology-dependent neutrophil fate decisions and a prognostic neutrophil-monocyte/macrophage interaction signature.
This study integrated single-cell RNA sequencing from 180,031 murine lung cells across seven acute lung injury models with spatial transcriptomics. It identified 13 neutrophil subtypes, etiology-dependent fate trajectories, a 26-gene neutrophil-monocyte/macrophage interaction index associated with sepsis mortality, and THBS1-CD36 signaling as a mechanistically actionable target.
Impact: The work challenges the assumption that neutrophils have a uniform role across acute lung injury etiologies. By linking spatially resolved cellular states to a prognostic signature and in vivo pathway blockade, it provides a mechanistic framework for precision treatment of infection-related lung injury and sepsis.
Clinical Implications: The 26-gene interaction index may support future molecular risk stratification in sepsis-associated lung injury, while THBS1-CD36 blockade could become a therapeutic strategy. Both require validation in human tissues, prospective cohorts, and appropriately powered interventional trials before clinical use.
Key Findings
- Single-cell profiles from 180,031 murine lung cells across seven acute lung injury models were integrated with spatial transcriptomics.
- Thirteen neutrophil subtypes and four broad neutrophil macro-states were identified, with sepsis and bacterial infection retaining neutrophils near an immature state.
- A 26-gene neutrophil-monocyte/macrophage interaction index showed prognostic value for sepsis mortality.
- Blocking THBS1-CD36 with CD36 peptide P(93-110) reduced inflammatory activation, promoted reparative macrophage polarization, and lowered circulating neutrophils in vivo.
Methodological Strengths
- Large single-cell dataset spanning seven infectious, sterile, and extrapulmonary injury models.
- Integration of single-cell, spatial transcriptomic, computational trajectory, prognostic, and in vivo validation approaches.
- Mechanistic testing of the THBS1-CD36 pathway rather than relying solely on descriptive omics associations.
Limitations
- The principal experimental evidence is derived from murine acute lung injury models and may not reproduce human sepsis biology.
- The prognostic 26-gene signature requires external validation in independent human cohorts.
- The therapeutic experiments do not establish clinical dosing, safety, or efficacy in patients.
Future Directions: Future studies should validate the neutrophil states and interaction index in human sepsis-associated acute lung injury, develop clinically feasible assays, determine whether THBS1-CD36 blockade improves organ outcomes, and define treatment windows and safety parameters.
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a life-threatening syndrome with heterogeneous etiologies and no effective pharmacological therapy. Although neutrophils are central mediators of lung injury, their functional diversity and interplay with monocyte/macrophage (Mo/MΦ) populations across etiologies remain poorly defined. Here, we integrated single-cell RNA-sequencing profiles from 180,031 murine lung cells across seven ALI models spanning infectious, sterile, and extrapulmonary insults to construct a multi-etiology neutrophil atlas. Augur identified neutrophils as the most transcriptionally perturbed immune population.
3. Antibiotic Resistance in the Pediatric Population in Pakistan (1996-2025): A Systematic Review and Meta-Analysis.
This PRISMA 2020 systematic review and meta-analysis synthesized 25 studies spanning 1996-2025 on pediatric antimicrobial resistance in Pakistan. Pooled bacteriologically confirmed sepsis or bloodstream infection positivity was 24.9%, associated mortality was 17.5%, multidrug-resistant Salmonella typhi/paratyphi reached 55.2%, and antibiotic prescribing was nearly universal while culture-guided use was uncommon.
Impact: The study quantifies a large, geographically important pediatric AMR burden directly relevant to sepsis treatment failure and mortality. Its findings support urgent national surveillance, microbiological diagnostics, antimicrobial stewardship, and empiric-therapy reform in Pakistan and comparable settings.
Clinical Implications: Empiric antibiotic protocols should be updated using local susceptibility data, with expanded blood-culture capacity and rapid diagnostics. Stewardship programs should reduce near-universal empiric prescribing, improve de-escalation, and prioritize surveillance for carbapenem-resistant, extended-spectrum beta-lactamase-producing, methicillin-resistant, and extensively drug-resistant organisms.
Key Findings
- Twenty-five studies from 1996-2025 were included using PRISMA 2020 methods.
- Pooled bacteriologically confirmed sepsis or bloodstream infection positivity was 24.9%, with pooled in-hospital mortality of 17.5%.
- Pooled multidrug resistance among Salmonella typhi/paratyphi isolates was 55.2%, increasing from 46.5% in 1996 to 92.9% in 2024 across individual studies.
- Antibiotic use ranged from 82.1% to 97%, while only 2.0% was culture-guided in the largest survey.
Methodological Strengths
- Longitudinal coverage from 1996 through 2025 across multiple international databases.
- PRISMA 2020 methodology, random-effects pooling, and synthesis of both resistance and sepsis-related outcomes.
- The review connects microbiological resistance patterns with mortality and prescribing practices.
Limitations
- Only 25 studies were available, and the included evidence likely varied in setting, pathogen ascertainment, and laboratory methods.
- Several pooled estimates were based on a limited number of studies, which may reduce precision and generalizability.
- The evidence base may be affected by publication bias and underrepresentation of rural or lower-resource facilities.
Future Directions: Pakistan should establish standardized national pediatric sepsis and AMR surveillance, strengthen laboratory networks, expand rapid susceptibility testing, and conduct prospective studies evaluating stewardship interventions and their effects on mortality and resistance trends.
BACKGROUND: Pakistan is facing a severe antimicrobial resistance (AMR) crisis, with the pediatric population at the highest risk. Despite widespread antibiotic use, there has been no long-term synthesis of pediatric-specific AMR data in the country until now. METHODS: We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines, searching PubMed, Scopus, Web of Science, Embase, and Google Scholar for studies (January 1996-December 2025) reporting antibiotic susceptibility data in children aged 0-18 years in Pakistan. Where three or more studies reported comparable outcomes, proportions were pooled using a DerSimonian-Laird random-effects model with Freeman-Tukey transformation; remaining findings were synthesized narratively.